Company Description
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocy...
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
Valuation
Price to Book Ratio
1.20
Enterprise Value to EBITDA
-0.91
Efficiency
Liquidity
Current Ratio
11.22
Quick Ratio
11.22
Cash Ratio
10.54
Profitability
Return on Assets
-43.02
Return on Equity
-49.07
Return on Total Capital
-45.45
Capital Structure
Total Debt to Total Assets
9.61
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Robert Alexander | 51 | 2017 | Chief Executive Officer & Director |
Dr. Adam L. Tomasi | 51 | 2017 | President & Chief Operating Officer |
Mr. Harlan Baird Radford | - | 2021 | Chief Financial Officer |
Dr. Ruby Casareno | - | - | Vice President-Technical Operations |
Dr. Craig Paterson | - | 2021 | SVP-Clinical Development & Medical Affairs |
Insider Actions
01/06/2023 |
Robert Alexander Chief Executive Officer; Director |
301,575 | Award at $0 per share. | 0 |
01/06/2023 |
Adam L. Tomasi President |
195,997 | Award at $0 per share. | 0 |
01/06/2023 |
Harlan Baird Radford Chief Financial Officer |
126,640 | Award at $0 per share. | 0 |
01/06/2023 |
Craig Paterson Chief Medical Officer |
102,690 | Award at $0 per share. | 0 |
12/02/2022 |
Robert Alexander Chief Executive Officer; Director |
15,152 | Derivative/Non-derivative trans. at $8.11 per share. | 122,882 |
12/02/2022 |
Adam L. Tomasi President |
9,783 | Derivative/Non-derivative trans. at $8.11 per share. | 79,340 |
12/02/2022 |
Harlan Baird Radford Chief Financial Officer |
3,843 | Derivative/Non-derivative trans. at $8.11 per share. | 31,166 |
12/02/2022 |
Craig Paterson Chief Medical Officer |
4,863 | Derivative/Non-derivative trans. at $8.11 per share. | 39,438 |
09/21/2022 |
Alta Partners Management Corp. Director |
475,000 | Acquisition at $5.02 per share. | 2,384,500 |
09/21/2022 |
NEA Management Co. LLC Director |
3,386,400 | Acquisition at $5.02 per share. | 16,999,728 |
09/21/2022 |
NEA Management Co. LLC Director |
597,600 | Acquisition at $5.02 per share. | 2,999,952 |
09/02/2022 |
Robert Alexander Chief Executive Officer; Director |
8,316 | Derivative/Non-derivative trans. at $4.54 per share. | 37,754 |
09/02/2022 |
Adam L. Tomasi President |
5,369 | Derivative/Non-derivative trans. at $4.54 per share. | 24,375 |
09/02/2022 |
Harlan Baird Radford Chief Financial Officer |
585 | Derivative/Non-derivative trans. at $4.54 per share. | 2,655 |
09/02/2022 |
Craig Paterson Chief Medical Officer |
1,129 | Derivative/Non-derivative trans. at $4.54 per share. | 5,125 |
09/02/2022 |
Margaret Fitzgerald General Counsel and Secretary |
335 | Derivative/Non-derivative trans. at $4.54 per share. | 1,520 |
06/02/2022 |
Robert Alexander Chief Executive Officer; Director |
8,084 | Derivative/Non-derivative trans. at $2.75 per share. | 22,231 |
06/02/2022 |
Adam L. Tomasi President |
5,219 | Derivative/Non-derivative trans. at $2.75 per share. | 14,352 |
06/02/2022 |
Harlan Baird Radford Chief Financial Officer |
2,274 | Derivative/Non-derivative trans. at $2.75 per share. | 6,253 |
06/02/2022 |
Craig Paterson Chief Medical Officer |
226 | Derivative/Non-derivative trans. at $2.75 per share. | 621 |
06/02/2022 |
Margaret Fitzgerald General Counsel and Secretary |
318 | Derivative/Non-derivative trans. at $2.75 per share. | 874 |
04/19/2022 |
Margaret Fitzgerald General Counsel and Secretary |
57,637 | Award at $0 per share. | 0 |
03/02/2022 |
Robert Alexander Chief Executive Officer; Director |
8,215 | Derivative/Non-derivative trans. at $5.38 per share. | 44,196 |
03/02/2022 |
Adam L. Tomasi President |
5,582 | Derivative/Non-derivative trans. at $5.38 per share. | 30,031 |
03/02/2022 |
Mark A. Asbury CLO |
1,680 | Derivative/Non-derivative trans. at $5.38 per share. | 9,038 |
02/25/2022 |
Robert Alexander Chief Executive Officer; Director |
529,323 | Award at $0 per share. | 0 |
02/25/2022 |
Adam L. Tomasi President |
344,060 | Award at $0 per share. | 0 |
02/25/2022 |
Harlan Baird Radford Chief Financial Officer |
237,608 | Award at $0 per share. | 0 |
02/25/2022 |
Mark A. Asbury CLO |
140,490 | Award at $0 per share. | 0 |
12/02/2021 |
Robert Alexander Chief Executive Officer; Director |
20,241 | Derivative/Non-derivative trans. at $78.69 per share. | 1,592,764 |
12/02/2021 |
Adam L. Tomasi President |
13,067 | Derivative/Non-derivative trans. at $78.69 per share. | 1,028,242 |
12/01/2021 |
Robert Alexander Chief Executive Officer; Director |
51,681 | Award at $0 per share. | 0 |
12/01/2021 |
Adam L. Tomasi President |
33,362 | Award at $0 per share. | 0 |
12/01/2021 |
Harlan Baird Radford Chief Financial Officer |
24,255 | Award at $0 per share. | 0 |
12/01/2021 |
Mark A. Asbury CLO |
26,003 | Award at $0 per share. | 0 |
MarketWatch News on ALLK
-
Alkermes, Allakos See Activist Action
- Barron's Online
-
8 Biotechs So Cheap Their Technology Is Effectively Free
- Barron's Online
-
Biotech M&A Has Been Slow This Year. Why It Might Get Busier.
- Barron's Online
-
Biotech stocks are a buy — especially these 18 picks
- Michael Brush
-
Allakos started at buy at BofA Securities
- Tomi Kilgore
-
Here’s What’s Working in the IPO Market Right Now: Almost Everything
- Barron's Online
-
Allakos stock jumps in afternoon trading
- Jaimy Lee
-
Allakos's stock rally adds over $2 billion to biotech's market cap
- Tomi Kilgore
-
Allakos's stock runs up 43% to record high
- Tomi Kilgore
-
Charting a bullish reversal, S&P 500 extends rally from major support
- Michael Ashbaugh
-
How 2018’s Major IPOs Performed
- Barron's Online
-
Glenn Krevlin Wants a Seat at Destination XL
- Barron's Online
-
ADP and Pershing Square Face Off
- Barron's Online
-
Biotech Allakos shares surge more than 70% in trading debut
- Ciara Linnane
-
Allakos shares surge 73% in trading debut
- Ciara Linnane
-
Biotech Allakos prices IPO at $18, above price range
- Ciara Linnane
-
Allakos prices IPO at $18 a share
- Ciara Linnane
Other News on ALLK
-
- Edgar Online - (EDG = 10Q, 10K)
-
AVCT, MSC and VTAQ among mid-day movers
- Seeking Alpha
-
Allakos prices ~$150M underwritten offering
- Seeking Alpha
-
Why Allakos Stock Is on Fire Today
- Motley Fool
-
AREC, TMC, AZRE among mid-day movers
- Seeking Alpha
-
CRMD, CALA and TBLT among mid-day movers
- Seeking Alpha
-
BLUE, NEPT and MNTS among mid-day movers
- Seeking Alpha
-
Allakos announces $250M shelf offering
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Biotech 101 Lecture 3: Looking At Major Biotech Catalysts
- Seeking Alpha
- Loading more headlines...